Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
The highest-value opportunities are emerging in obesity care, type 2 diabetes management, oral formulations, cardiometabolic outcome programs, combination therapies and manufacturing scale-up
It works at the cellular level
Participants receive close monitoring, and outcomes dont always translate perfectly into everyday care
| 1st Phorm
Synthesis and in vitro evaluation of a peptidomimetic inhibitor targeting the Src homology 2 (SH2) domain of STAT6
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
